Loading...

STOK STOKE THERAPEUTICS INC Expansion Plans 8-K Filing

STK

STK

STOKE THERAPEUTICS INC

(STOK)

2025 8-K

Data Presentation Announcement

Financial Results Report

CEO Appointment

Voting Frequency Decision

Product Expansion

Product Expansion

Financial Statements

Management Changes

Licensing Agreement

FDA Breakthrough Designation

Q3 Earnings Report

Lawsuit Settlement

Earnings Reports

Departure of Officer

Annual Meeting of Stockholders

Financial Results Announcement

Appointment of CFO and Resi...

Public Offering

New Data Announcement

Financial Results Announcement

Regulation FD and Other Events

Lease Extension

Announcement of Clinical Da...

Earnings Reports

Special Meeting Approval

Appointment of Director

Earnings Reports

Product Updates

Annual Meeting of Stockholders

Financial Results Announcement

FDA Approval for Higher Sin...

Financial Results

Amended and Restated Bylaws...

Business Update

External Links:

Stoke Therapeutics announced plans for a Phase 3 study of zorevunersen, a potential treatment for Dravet syndrome, with a target start date in mid-2025 and data expected by the end of 2027.

AI Assistant

STOKE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.